|
|
|
| Clinical effect of Yinhua Miyanling Tablets in treatment of cystitis glandularis |
| YUAN Jincheng1 ZHANG Shirui1 QIU Jianhong1 ZHAO Xinhong1 BI Yuwang2#br# |
1.Department of Urology, the 980th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army, Hebei Province, Shijiazhuang 050082, China;
2.Department of Information, the 980th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army, Hebei Province, Shijiazhuang 050082, China |
|
|
|
Abstract Objective To investigate the effect of Yinhua Miyanling Tablets in the treatment of cystitis glandularis (CG). Methods A total of 82 male CG patients who underwent transurethral plasma vaporectomy and postoperative chemotherapy combined with bladder infusion were selected from January 2016 to March 2021 in the 980th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army. They were divided into control group and observation group according to the random number table method, with 41 cases in each group. The control group was given Tamsulosin Hydrochloride Sustained-Release Capsules after operation, and the observation group was additionally given Yinhua Miyanling Tablets on this basis. The treatment lasted for six months, the clinical efficacy, urodynamics indexes (maximum flow rate, average flow rate, residual urine volume), serum levels of inflammatory cytokines (interleukin-8 [IL-8], IL-17 and tumor necrosis factor-α [TNF-α]) were compared between two groups. Results The total effective rate in observation group was higher than that in control group (P < 0.05). After treatment, the maximum flow rate and average flow rate of two groups were higher than those before treatment, while the residual urine volume was lower than that before treatment (P < 0.05); the maximum flow rate and average flow rate in observation group were higher than those in control group, while the residual urine volume was lower than that in control group (P < 0.05). After treatment, The levels of IL-8, IL-17, and TNF-α in two groups were lower than those before treatment, and observation group was lower than control group (P < 0.05). Conclusion Yinhua Miyanling Tablets plays a positive role in the treatment of CG, which may be related to its anti-inflammatory effect.
|
|
|
|
|
|
[1] Zouari S，Bouassida K，Ahmed KB，et al. Acute urinary retention due to benign prostatic hyperplasia associated with cystitis glandularis in a 22-year-old patient [J]. Pan Afr Med J，2018，30：30.
[2] Hua H，Gao Y，Lin J，et al. Quantitative Analysis of Enhanced Computed Tomography in Differentiating Cystitis Glandularis and Bladder Cancer [J]. Biomed Res Int，2020，2020：4930621.
[3] 陈跃东，曾彦恺，白培德，等.炎症细胞在女性腺性膀胱炎膀胱黏膜下的浸润情况及临床意义[J].中华泌尿外科杂志，2018，39（8）：569-572.
[4] Qu Y，Chen X，Cui Y，et al. Changes of bladder mucosal inflammatory factors and prognosis in cystitis glandularis [J]. Int J Clin Exp Pathol，2018，11（7）：3591-3597.
[5] Feng Z，Shi H，Liang B，et al. Bioinformatics and experimental findings reveal the therapeutic actions and targets of pachymic acid against cystitis glandularis [J]. Biofactors，2021，47（4）：665-673.
[6] 王宁，叶章群，陈志强.腺性膀胱炎的新认识[J].中华泌尿外科杂志，2017，38（3）：235-237.
[7] 苗康，袁宝，王德鑫.复方苦参注射液联合羟喜树碱膀胱灌注治疗电切术后腺性膀胱炎临床观察[J].辽宁中医杂志，2020，47（9）：97-99.
[8] 中华医学会泌尿外科学分会，腺性膀胱炎诊治专家共识编写组.腺性膀胱炎临床诊断和治疗中国专家共识[J].中华泌尿外科杂志，2020，41（8）：566-568.
[9] 赵海涛，樊烜婷，李超.腺性膀胱炎的诊疗进展[J].内蒙古中医药，2021，40（2）：128-130.
[10] 张学宝，张其强，刘楚，等.腺性膀胱炎的诊疗研究进展[J].国际外科学杂志，2021，48（3）：207-211.
[11] 冀鲁，仲冰.单纯经尿道切除术及其联合术后吡柔比星灌注治疗腺性膀胱炎的临床比较[J].湖南师范大学学报（医学版），2017，14（5）：95-97.
[12] Ni Y，Zhao S，Yin X，et al. Intravesicular administration of sodium hyaluronate ameliorates the inflammation and cell proliferation of cystitis cystica et glandularis involving interleukin-6/JAK2/Stat3 signaling pathway [J]. Sci Rep，2017，7（1）：15892.
[13] 苏蕴瑜，赵冬，林谋清，等.口服八正散联合吡柔吡星膀胱灌注治疗腺性膀胱炎的临床观察[J].内蒙古中医药，2020，39（1）：38-40.
[14] 刘春林，张光荣，皮持衡.皮持衡治疗“腺性膀胱炎”经验总结[J].江西中医药，2018，49（3）：21-23.
[15] 闵立贵，牛宏伟.腺性膀胱炎（附172例报告）[J].中华泌尿外科杂志，2003，24（5）：308-310.
[16] 杨旺秋.腺性膀胱炎TUR术后膀胱内灌注药物的概述[J].国际泌尿系统杂志，2016，36（4）：613-615.
[17] 樊鑫，董安珂，师磊，等.经尿道膀胱电切术联合氟尿嘧啶热灌注化疗治疗腺性膀胱炎126例疗效观察[J].山东医药，2018，58（11）：77-79.
[18] 徐遵礼，朱建平，石格荣.两种方法治疗腺性膀胱炎疗效观察[J].人民军医，2018，61（8）：722-725.
[19] 杨林，南勋义.腺性膀胱炎膀胱灌注治疗无效[J].现代泌尿外科杂志，2012，17（6）：604-605.
[20] 余明主，郑慧杰，曹卫霞，等.银花泌炎灵片联合左氧氟沙星治疗急性尿路感染的临床观察[J].中国医师杂志，2019，21（10）：1571-1574.
[21] 王志刚，陈铭，邱云桥，等.银花泌炎灵片联合抗菌药物治疗绝经后女性下尿路感染的临床效果[J].中国医药，2018，13（8）：1212-1215.
[22] 宁克勤，陈磊，欧阳斌，等.银花泌炎灵片治疗Ⅲ型前列腺炎湿热下注证：随机、双盲、安慰剂平行对照、多中心临床试验[J].中华中医药学刊，2021，39（10）：187-190.
[23] 苏贻洲，刘成，黄永斌.银花泌炎灵片预防膀胱镜下双J管拔除术后尿路感染的疗效观察[J].中国现代医学杂志，2015，25（13）：108-110.
[24] 樊荣，羿国娟，鲁兰，等.绿原酸及其13种体内主要代谢物的体外抗菌作用研究[J].中草药，2020，51（24）：6239-6245.
[25] 张文婷，苗润培，赵启菡，等.银花泌炎灵片治疗尿路感染临床与基础研究[J].中国中药杂志，2019，44（11）：2403-2410.
[26] 赛景影.银花泌炎灵片抗炎作用及其机制研究[D].长春：吉林大学，2015.
[27] 张文婷，苗润培，赵启菡，等.银花泌炎灵片联合莫西沙星治疗慢性前列腺炎湿热瘀阻证的临床研究[J].现代药物与临床，2021，36（2）：293-297. |
|
|
|
